Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laxai Pharma Acquires OSR Solutions
Laxai Pharma has completed the asset purchase of OSR by investing $3.6m financed through the issuance and sale of debt and equity securities. The company now has 60.1m
Laxai Pharma has completed the asset purchase of OSR by investing $3.6m financed through the issuance and sale of debt and equity securities. The company now has 60.1m
Eli Lilly has posted a net income of $1.25bn, or $1.13 per diluted share, a decrease of 5%, compared to $1.31bn, or $1.20 per diluted share, for the
Amylin Pharmaceuticals has posted total revenues of $174.13m, which includes net product sales of $172.3m, for the first quarter 2010, compared to $180.4m for the year ago period.
As per the agreement, Dimerix is expected to use its GPCR-HIT platform and insights into the ability of G-Protein Coupled Receptors (GPCRs) to form complexes, called heteromers, to
Progen Pharmaceuticals said that the new contract further validates PharmaSynth as an important Australian based contract manufacturer with expertise in recombinant proteins, bacterial and viral vaccines, whole cell
The PCR system offers a number of performance and usability enhancements that are expected to advance the understanding of molecular biology in the pharmaceutical discovery and clinical research
Sequenom said that with the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY
The expansion, which is scheduled to be completed by next month, marks Baxter’s third capacity expansion, further augmenting Halle’s complete range of resources to support early-phase drug formulation
OSI Pharmaceuticals said that the new approval for Tarceva was based on data from the pivotal Phase III Saturn study. Saturn showed that Tarceva given as a maintenance
Diquafosol was licensed for certain ophthalmic uses from Inspire and Diquas Ophthalmic Solution 3% was developed by Santen as a treatment for dry eye. Reportedly, in clinical studies